摘要急性髓细胞白血病(AML)为异质性血液系统恶性肿瘤.AML除与相关基因突变、染色体变异相关以外,与异常的表观遗传学改变亦有着密切的关系.DNA与组蛋白甲基化修饰均为AML重要的表观遗传学改变,并且表观遗传学改变是可逆的,因此其有可能成为治疗AML的新靶点.目前,AML治疗主要采用传统的诱导化疗方案,但是疗效欠佳.为了进一步提高AML的临床疗效,亟需进一步阐明AML的发病机制,并且针对新的治疗靶点,研发新的治疗药物或创新联合药物治疗方案,以实现AML的个体化治疗.笔者拟就AML相关异常甲基化修饰的基因突变及DNA甲基化转移酶抑制剂(DNMTi)在治疗AML中的研究进展进行综述.

abstractsAcute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.In addition to the gene mutation and chromosome variation,AML is closely related to the abnormal epigenetic changes.DNA and histone methylation modification are important epigenetic alterations and as the epigenetic alteration are reversible,so they may be new targets for AML therapy.At present,AML is treated by traditional induction chemotherapy,but the curative effect is poor.In order to further improve the clinical curative effect,further study of the pathogenesis of AML and new drugs against new therapeutic target and innovative way to combine the drug to realize the individualized treatment of AML are needed.This review focuses on the progress in the study of AML related aberrant methylation modified mutant genes and DNA methyltransferase inhibitor (DNMTi) in the treatment of AML.